BioSpecifics Announces Positive Data From Phase 2a Study Of CCH For Cellulite

(RTTNews) - BioSpecifics Technologies Corp. (BSTC) Thursday announced positive, statistically significant results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum or CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy.

Cellulite describes a condition where lobules of subcutaneous adipose tissue extend into the dermal layer. Cellulite can involve the loss of elasticity or shrinking of collagen cords that attach the skin to lower layers of muscle.

The results showed that all three doses of CCH used in the study, including a low, medium and high dose, showed an improvement in the appearance of cellulite as measured by the trial endpoints of physician and patient-assessed improvements.

CCH was well-tolerated by all dose groups. Most adverse events were mild to moderate and primarily limited to the local injection area.

BioSpecifics is a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU.

BSTC closed up 6.5 percent on Thursday at $30.92.